Baidu
map

心律失常7大原则,你了解几个?

2015-06-12 伊文 心在线

急性心律失常可发生于任何年龄、各级医院和临床各科。若不能迅速对其做出正确判断,并给予及时处理,可导致血流动力学急剧恶化,危及生命。临床医师应熟悉紧急抢救流程,规范抗心律失常药物应用,尤其需要遵循7大处理原则:1、识别和纠正血流动力学障碍心律失常急性期,首先应根据血流动力学决定处理原则。血流动力学不稳定,如不及时处理,病情继续进展,严重者可危及生命,此

急性心律失常可发生于任何年龄、各级医院和临床各科。若不能迅速对其做出正确判断,并给予及时处理,可导致血流动力学急剧恶化,危及生命。临床医师应熟悉紧急抢救流程,规范抗心律失常药物应用,尤其需要遵循7大处理原则:

1、识别和纠正血流动力学障碍

心律失常急性期,首先应根据血流动力学决定处理原则。血流动力学不稳定,如不及时处理,病情继续进展,严重者可危及生命,此时不应苛求完美的诊断流程,而应追求抢救治疗的效率,以免贻误抢救时机。血流动力学不稳定的异位快速心律失常应尽早采用电复律终止,严重的缓慢性心律失常要尽快采用临时起搏治疗。

血流动力学相对稳定者,可根据心电图特点、临床症状,结合病史及体格检查进行诊断及鉴别诊断,选用适当的治疗策略,所选药物以安全为主,不应加重病情或使病情复杂化。

2、重视基础疾病和诱因的治疗

心律失常是否合并器质性心脏病直接决定处理策略和影响预后,是一个不可忽略的考量因素。在心律失常紧急救治的同时,不可忽略基础疾病的治疗和相关病因的纠正,尤其是心肌缺血和心功能不全。相关基础疾病的急性处理,应根据相应指南的推荐进行。

基础疾病和心律失常可互为因果,紧急救治中孰先孰后,取决于何为主要矛盾。若心律失常最为紧急,应首先处理心律失常。如心律失常继发于急性心肌梗死,仅表现为室性早搏,不危及生命,可先治疗急性心梗。

3、衡量效益与风险比

对危及生命的心律失常应采取积极、有效的措施进行控制,挽救生命。对未危及生命的心律失常的处理,更多考虑治疗措施的安全性,避免过度治疗引发新的风险。同时需要注意的是,风险与效益比可随病情的变化而改变,应灵活调整治理措施。

4、对心律失常本身的处理

若心律失常本身造成严重的血流动力学障碍,终止心律失常应为治疗的首要任务。如室上性心动过速、症状明显的心房颤动,导致患者出现不可耐受的症状,应采取及时的终止措施。而某些心律失常(如新出现的房颤、室早、房早)并不一定需要立刻终止,可先适当用药,缓解症状。

5、正确处理治疗矛盾

在心律失常紧急处理时经常遇到治疗矛盾,如平时心动过缓,突然发生快速房颤;心律失常发作时血压偏低需要用胺碘酮。此时需衡量矛盾的主要方面(即当前对患者危害较大的病因),优先处理主要矛盾。如房颤合并心衰,治疗过程中出现心动过缓,但无严重的血流动力学障碍,此时心动过缓可暂且忽略。

6、兼顾治疗与预防

(1)心律失常易复发,纠正后应采取预防措施,减少复发。基本的预防措施包括加强基础疾病的治疗、控制诱发因素、结合患者的病情确定是否采用抗心律失常药物治疗。临床上并非所有的心律失常都需给予治疗,如对于首次发生房颤的患者,并不主张立即给予抗心律失常药物长期预防。

(2)恶性室性心律失常终止后一般均需给予药物治疗,以预防复发。

(3)在紧急处理后,应对心律失常的远期治疗有所考虑和建议。

7、抗心律失常药物的联合使用

在电复律之前一般只用一种抗心律失常药,不主张序贯用药,不主张联合用药,以免出现不良的药物相互作用和促心律失常作用。应用一种静脉抗心律失常药疗效不满意,应先审查用药是否规范、剂量是否足够。不建议短期内更换或合用另一种静脉抗心律失常药物,宜考虑采用非药物的方法如电复律或食管调搏等。只有顽固性的、反复发作的恶性心律失常才考虑联合用药。

[本文内容根据阜外心血管病医院朱俊教授《心律失常紧急处理专家共识》专家讲座整理]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-25 huaxipanxing

    看看

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-14 qinweihan19

    心内科用药是大学问

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-13 chenguoyan

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-13 chenguoyan

    谢谢作者

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-13 chenguoyan

    非常实用

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-13 chenguoyan

    写的不脆

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-12 da1215225

    今天知道了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-12 18619c0a62m

    很有用

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=29405, encodeId=0dea29405cb, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=163, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Thu Jun 25 23:46:00 CST 2015, time=2015-06-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27593, encodeId=929c2e593b3, content=心内科用药是大学问, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=efcb1614039, createdName=qinweihan19, createdTime=Sun Jun 14 14:23:00 CST 2015, time=2015-06-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27472, encodeId=838d2e47272, content=错, beContent=null, objectType=article, channel=null, level=null, likeNumber=195, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27473, encodeId=10852e47310, content=谢谢作者, beContent=null, objectType=article, channel=null, level=null, likeNumber=209, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27474, encodeId=69282e47400, content=非常实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:29:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27471, encodeId=98802e471f2, content=写的不脆, beContent=null, objectType=article, channel=null, level=null, likeNumber=147, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=db141627504, createdName=chenguoyan, createdTime=Sat Jun 13 03:28:00 CST 2015, time=2015-06-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27302, encodeId=fcef2e302aa, content=今天知道了, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=41521628038, createdName=da1215225, createdTime=Fri Jun 12 16:36:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27278, encodeId=dd022e2781f, content=很有用, beContent=null, objectType=article, channel=null, level=null, likeNumber=111, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12a31627589, createdName=18619c0a62m, createdTime=Fri Jun 12 14:47:00 CST 2015, time=2015-06-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=27257, encodeId=b3692e2570e, content=很好,切中要害!, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLCEEr4dM45RatXXGAkFCicnNYiasFiaRicicO1YWsIeTFOhgapauqib8Z8TChNB3ttVC5RqNHptDvAxA72Q/0, createdBy=a82a1611288, createdName=yydlt, createdTime=Fri Jun 12 11:12:00 CST 2015, time=2015-06-12, status=1, ipAttribution=)]
    2015-06-12 yydlt

    很好,切中要害!

    0

相关资讯

杨延宗&常栋:慢性心房颤动导管消融再争论

1998年,法国Haissaguerre教授报道了肺静脉点消融治疗心房颤动(房颤),从此开创了房颤的消融时代。近十余年来,房颤导管消融迅速进展,方兴未艾,阵发性房颤消融已从Ⅱa类推荐上升至Ⅰ类推荐。 更重要地是,随着导管消融治疗房颤技术的迅速发展和器械设备的不断提高,房颤消融范围早已突破了“阵发性房颤”的范畴,慢性房颤(持续性房颤、长期持续性房颤、永久性房颤)消融获得了越来越多的经验

朱俊:抗心律失常药物的定位

抗心律失常药物的定位 随着器械治疗的进展,近年来β受体阻滞剂之外的抗心律失常药物在室性心律失常治疗中的地位明显下降,尤其是长期治疗。但共识还是十分清楚地给出了各种情况下抗心律失常药物治疗的定位。 在非持续性室性心律失常治疗中,可用β受体阻滞剂或钙拮抗剂,目的是改善症状(Ⅱb,C)。共识指出,盐酸普罗帕酮或氟卡胺不应用于左室功能不全、心肌缺血或有心肌瘢痕者,这是整个共识唯一的ⅢA类推

盘点2014心律失常研究进展

1.干预自主神经系统有助于抑制心律失常 一项研究表明,对于收缩性心衰合并难治性室速患者,肾动脉去神经术使室速发生频率从11.0 ± 4.2次/月降至0.3 ± 0.1次/月。虽然该研究样本量小(只有4例),非盲性,纳入患者属于急性病程并同时接受其它治疗,而且SYMPLICITY HTN 3研究未能证实肾脏去神经有效治疗顽固性高血压,但是干预自自主治疗心律失常的理念依旧令人振奋。 2

专家点评2014年心律失常领域新近进展

2014已近年末,心血管内科的医生们大概对自己所在领域今年的新亮点和关注的热点非常感兴趣,所以为了满足大家的好奇心与求知欲,阜外医院第一病区主任姚焰教授、上海交通大学医学院附属瑞金医院心脏科副主任吴立群教授等多位权威专家为大家解析心血管领域2014最新技术进展,以下是姚焰教授关于房颤消融最新进展的解读,请各位“尽情享用”。 冷冻消融治房颤更简便更安全 心房颤动(房颤)是临床较常见的

专家为您解答2014心律领域五大问题

一、房颤射频消融围术期抗凝:华法林仍为首选? 2014年4月17日在线发表于《循环》(Circulation)杂志的COMPARE研究显示,与停用华法林而用低分子量肝素过渡治疗相比,心房颤动(房颤)射频消融期间持续用华法林抗凝治疗可减少围术期卒中和轻微出血事件。 COMPARE研究设计为多中心、前瞻性、开放标签、随机、平行分组,共纳入1584例CHADS2评分≥1的受试者,按1

Baidu
map
Baidu
map
Baidu
map